Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Osama Mufti

Glaucoma Specialist Wesley Chapel, FL Medical Doctor

NPI 1629638374 CMS profile 7066375

27356 Cashford Cir, Wesley Chapel, FL 33544

Open in the dashboard

General payments

$2,543

52 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Osama Mufti of Wesley Chapel, FL is reported in the CMS Open Payments database as having received $2,543 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $771 29
2024 General $646 9
2023 General $439 5
2022 General $166 3
2021 General $125 1
2020 General $396 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Osama Mufti
  • Glaucoma Specialist median
  • Middle half of Glaucoma Specialist
  • National median

In program year 2025, general payments to Osama Mufti were reported at $771. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.

Show as a table
Year Osama Mufti Glaucoma Specialist median Middle half National median
2019 $0 $433 $150–$1,170 $163
2020 $396 $242 $74–$693 $114
2021 $125 $324 $122–$936 $132
2022 $166 $399 $121–$1,081 $149
2023 $439 $458 $190–$1,208 $160
2024 $646 $558 $215–$1,359 $164
2025 $771 $597 $244–$1,607 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Alcon Vision LLC $440 8 payments
  2. Glaukos Corporation $379 5 payments
  3. AbbVie, Inc. $266 8 payments
  4. Janssen Pharmaceuticals, Inc $243 2 payments
  5. Sight Sciences, Inc. $228 6 payments
  6. Regeneron Healthcare Solutions, Inc. $149 2 payments
  7. Omeros Corporation $125 1 payment
  8. Catalyst Pharmaceuticals, Inc. $125 1 payment
  9. Allergan Inc. $100 1 payment
  10. Harrow Eye, LLC $89 1 payment
  11. Other $400 17 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,443 51 payments
  2. Education $100 1 payment
Products named General payments · program years 2020–2025
  1. Clareon $299 2 payments
  2. XARELTO $243 2 payments
  3. OMNI SURGICAL SYSTEM $228 6 payments
  4. SION SURGICAL INSTRUMENT $178 3 payments
  5. iStent Trabecular Micro-Bypass System Model iS3 $176 2 payments
  6. Omidria $153 2 payments
  7. EYLEA $149 2 payments
  8. iDose $146 1 payment
  9. FYCOMPA $125 1 payment
  10. UBRELVY $122 1 payment
  11. Other $1,349 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

43

Median for Ophthalmology: 891

Drug cost

$372

Median for Ophthalmology: $68,233

Branded share of claims

48.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 21 $212
Latanoprost Generic 22 $160

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IHEEZO
  • Harrow Eye, LLC $18
$18 — —
TOBRADEX ST
  • Harrow Eye, LLC $18
$18 — —
FLAREX
  • Harrow Eye, LLC $18
$18 — —
VERKAZIA
  • Harrow Eye, LLC $18
$18 — —
NATACYN
  • Harrow Eye, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Glaucoma Specialist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record